SLC39A3

Across TCGA pan-cancer cohorts, SLC39A3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC39A3 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC39A3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC39A3 expression acts as an unfavorable survival marker.

STAD, LUSC, and HNSC are the cancer types where SLC39A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.677	.004	18	view →
LUSC	DFS	Median	II,III,IV	0.219	0.616	.001	11	view →
HNSC	OS	Median	III,IV	0.174	0.656	.040	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC39A3–STAD (OS)

Open the STAD breakdown →